Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

284 results about "Astrocyte cells" patented technology

Cell Biology of Astrocyte Cells: Protocols, Transfection. Astrocytes, or astroglia, are the star shaped glial cells that reside in the brain and spinal cord. They are the most numerous cells in the human brain, performing many tasks.

Grass carp brain astrocyte line and application thereof

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Pharmaceutical composition for prevention or treatment of degenerative brain diseases comprising selexipag

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising selexipag or a pharmaceutically acceptable salt thereof as an active ingredient. Selexipag inhibits the expression and production of pro-inflammatory or inflammatory cytokines in brain tissue, inhibits the activity of microglia or astrocytes, inhibits NLRP3 inflammasome activity and CDK6 expression, reduces amyloid plaques, increases the expression of the amyloid beta-degrading enzyme IDE, and inhibits the hyperphosphorylation of tau protein and the expression of tau kinase, and thus can be effectively used as a novel therapeutic agent for the prevention or treatment of degenerative brain diseases, cognitive disorders, learning disabilities, or memory disorders.
Owner:DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Application of miR-124-3p in preparation of medicine for treating cerebral hemorrhage secondary injury and medicine

The invention belongs to the technical field of medicine, and particularly provides application of miR-124-3p in preparation of a medicine for treating cerebral hemorrhage secondary injury and the medicine, it is found for the first time that miR-124-3p participates in regulation and control of reactive astrocytes of neuroinflammation caused by cerebral hemorrhage, inhibition of injury of the astrocytes to neurons is achieved, and the application of miR-124-3p in preparation of a medicine for treating cerebral hemorrhage secondary injury is achieved. The compound has a wide application prospect in preparation of medicines related to neuroinflammation after cerebral hemorrhage.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Application of PDCD4 expression inhibitor in preparation of traumatic craniocerebral injury repair medicine

PendingCN119405810AInfection effect is goodExpression level is stableNervous disorderGenetically modified cellsMedicinePharmaceutical drug
The invention belongs to the technical field of biological medicines, and particularly relates to application of a PDCD4 expression inhibitor in preparation of a traumatic craniocerebral injury repair medicine. The research finds that the PDCD4 gene is positioned in a cell nucleus of an astrocyte, the PDCD4 is transferred to cytoplasm after traumatic craniocerebral injury, and an inhibition effect is generated on autophagy. Based on the research result, the invention provides the sh-PDCD4 lentivirus which is relatively good in lentivirus infection effect and can stably knock down the expression level of PDCD4, and the sh-PDCD4 lentivirus remarkably promotes the autophagy of astrocytes and has a relatively good application prospect on targeted drugs for clinically developing and treating traumatic craniocerebral injury.
Owner:THE FIRST PEOPLES HOSPITAL OF NANTONG

Method for producing three-dimensional cell culture, method for culturing three-dimensional cell culture, three-dimensional cell culture, and method for evaluating test substance

The present invention addresses the problem of providing: a method for producing a three-dimensional cell culture including human-derived neurons, astrocytes, and microglia that can mimic the function of a human brain, and a method for culturing for said three-dimensional cell culture; a three-dimensional cell culture including human-derived neurons, astrocytes, and microglia that can mimic the function of a human brain; and a method for evaluating a test substance using the three-dimensional cell culture. The present invention provides a method for producing a three-dimensional cell culture, the method including: a step for adding human-derived astrocytes, human-derived neurons, and human-derived microglia to a culturing container prior to co-culturing of the cells; and a step for co-culturing the astrocytes, the neurons, and the microglia in the culturing container, wherein the proportion of the astrocytes to all cells added to the culturing container is 30% or more.
Owner:FUJIFILM CORP

Bipeptide modified bionic nano-vesicle as well as preparation method and application thereof

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Carbamoyl lipid having cyclic group in side chain, lipid nanoparticles thereof, and pharmaceutical composition thereof

PCT designated stage expiredWO2025143163A1Organic active ingredientsPowder deliverySide chainNanoparticle
The present inventors have found a carbamoyl lipid having a cyclic group in a side chain, which can form lipid nanoparticles, and have revealed that the lipid nanoparticles containing, as a constituent, the carbamoyl lipid having a cyclic group in a side chain according to the present invention can express a protein in astrocytes or hepatocytes. The lipid nanoparticles containing, as a constituent, the carbamoyl lipid having a cyclic group in a side chain according to the present invention contain a nucleic acid inside thereof and are expected as a component of a pharmaceutical composition useful for prevention and / or treatment of an astrocyte-related disease.
Owner:ASTELLAS PHARMA INC

Application of combination of achyranthes bidentata polypeptide and human umbilical cord mesenchymal stem cell exosome in preparation of medicine for preventing and / or treating Parkinson's disease

The invention belongs to the technical field of biological medicines, and relates to application of achyranthes bidentata polypeptide combined with human umbilical cord mesenchymal stem cell exosome in preparation of a medicine for preventing and / or treating Parkinson's disease, the achyranthes bidentata polypeptide combined with the human umbilical cord mesenchymal stem cell exosome is used for treating mice, and 1-methyl-4-phenyl-1, 2, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4 The method comprises the following steps: carrying out Parkinson model (PD) modeling on a mouse by using 2, 3, 4, 6-tetrahydropyridine (MPTP); it is found that the treatment can significantly relieve PD related symptoms, for example, the number of dopaminergic neurons in a nigra part is recovered, expression of tyrosine hydroxylase in a middle brain part is improved, movement and olfactory dysfunction of a PD model mouse is relieved, activation of olfactory bulbs and microglia and astrocytes in the middle brain part is reduced, and activity of neurons in the olfactory bulbs is improved.
Owner:YAOSHUNZE BIO MEDICAL NANJING CO LTD

Application of astrocyte-derived extracellular vesicles carrying Tau in auxiliary diagnosis of progressive suprakaryotic paralysis

The invention discloses application of astrocyte-derived extracellular vesicles carrying Tau in auxiliary diagnosis of progressive suprakaryotic paralysis, and belongs to the technical field of biomedicine. The specific Tau protein antibody and the anti-glutamic acid transporter 1 antibody are labeled by fluorescence, astrocyte-derived extracellular vesicles carrying Tau in the plasma are accurately detected, PSP patients, PD patients and healthy people can be accurately distinguished by analyzing the concentration of astrocyte-derived EVs carrying Tau in the plasma, and the kit has the advantages of high sensitivity, high sensitivity, high sensitivity and the like. An efficient PSP diagnosis biomarker and a diagnosis model are provided, and a new experience method and technical support are provided for PSP diagnosis and identification.
Owner:BEIJING NEUROSURGICAL INST

Gene therapy for repairing phosphorus homeostasis in brain by targeting astrocytes

PendingCN119326898ACompound screeningOrganic active ingredientsPhosphate homeostasisMedicine
The invention relates to an intracerebral phosphorus homeostasis accelerant and application thereof. Specifically, a gene compensation therapy for targeting glial cells, especially astrocytes, is developed on the basis of a molecular cytology mechanism of the intracerebral phosphorus homeostasis, and can be used for repairing the intracerebral phosphorus homeostasis imbalance condition, so that the occurrence of calcification is inhibited, or the further progress of intracerebral calcification is inhibited, and the intracerebral phosphorus homeostasis is inhibited. And clinical nervous system symptoms of related patients are improved.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI +1

Method for regulating neurotoxic reactive astrocytes, regulator and application

TMEM164 and the like can prevent and inhibit the induced activation of neurotoxic reactive astrocytes and neuron death in neurodegenerative diseases. The present invention relates to the field of neuroscience, in particular the medical treatment of neurodegenerative diseases. TMEM164, SOC18, CAPN15 and the like are identified as early reaction regulatory factors of neurotoxic astrocyte reactivity, and it is found that for example, TMEM164 overexpression can prevent induced activation of neurotoxic reactive astrocytes and neuron death in mouse and human astrocytes, as well as in an inflammation-induced PD mouse model and a 5XFAD mouse model; therefore, a basis is provided for treatment of neurodegenerative diseases related to neurotoxic reactive astrocytes.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI

Method for recovering microglia and astroglia and application thereof

Methods for treating Alzheimer's disease and other neurodegenerative disorders in which the capacity of microglia and / or astrocytes has been altered and impaired are described. The method comprises the step of carrying out brain targeting on PD-L1 by using a brain targeting nanogel which is loaded with a PDL1 antibody and is functionalized by two specific targeting ligands. The nanogel can successfully cross the blood brain barrier to release the antibody, reduce the expression of PD-L1 in the brain, and maintain the integrity of BBB at the same time.
Owner:UNIVERSITY OF SOUTH CAROLINA

Connexin 43 antibodies and use thereof

The present disclosure generally relates to compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or condition or a neurodegenerative disease such as spinal cord injury.
Owner:ALAMAB THERAPEUTICS INC

Application of hypoxia pretreatment extracellular vesicles / miR-27b-3p in ischemic stroke treatment

The invention discloses an application of a hypoxia pretreated extracellular vesicle / miR-27b-3p in the treatment of ischemic stroke. The research proves that both the neuron-derived EV and H-EV can promote in-vivo and in-vitro MCAO repair. The two vesicles secreted by neuronal cells can significantly influence phenotypic change and apoptosis of astrocytes, wherein the effect of H-EV is more obvious than that of EV. Besides, the research result shows that H-EV secreted by neurons can regulate a PI3K / AKT signal channel by transmitting miR-27b-3p, so that astrocytes are promoted to be converted from the A1 phenotype to the A2 phenotype. The research of the invention provides a new therapeutic target and strategy for treating ischemic stroke.
Owner:CHONGQING MEDICAL UNIVERSITY

Construction method and application of animal model of conditional knock-down dynactin of astrocytes

The invention discloses a construction method of a conditional knock-down dynactin animal model of astrocytes and an application of the animal model of the conditional knock-down dynactin animal model of the astrocytes. According to the method, a Dctn1LoxP gene knock-in mouse is hybridized with an Aldh1l1-Cre / ERT2 transgenic mouse, a target genotype mouse is obtained through three rounds of breeding, 100mg / kg Tamoxifen is continuously injected into the intraperitoneal cavity of the 2-month-old mouse for 5 days, and specific knock-down of dynactin in brain and spinal astrocytes is realized, including knockout of p150Glue and reduction of DCTN4, p50 and Arp1alpha protein levels. The model has the advantages of being high in specificity, permanent in intervention aging and capable of covering multiple life stages, the defects of a traditional model are overcome, the model can be used for researching the influence of dynactin on astrocyte neurobiological functions, a reliable tool is provided for screening related targets of nervous system diseases, and the model has important application value.
Owner:BEIJING GERIATRIC HOSPITAL

Anxiety disorder drug target and application thereof

The invention belongs to the technical field of biological medicine, and particularly provides application of EAAT2 as a drug target to screening of drugs for improving anxiety disorder. The drug target EAAT2 is mainly expressed on astrocytes, the research finds that the expression level of the EAAT2 is closely related to the anxiety state, and the anxiety disorder can be improved by regulating and controlling the target through a specific compound and a specific adenovirus vector. A brand-new drug target and a new treatment means and thought are provided for treatment of anxiety disorder and drug research and development.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Use of a t1r3 agonist sucralose in the alleviation of alzheimer's disease and related cognitive impairments

The application discloses application of T1R3 agonist sucralose in relieving Alzheimer's disease and related cognitive impairment, and aims at brain glucose metabolism disorder and cognitive decline problem, and the application takes sucralose as the only pharmaceutical active ingredient, corrects brain glucose metabolism disorder through targeting brain astrocyte sweet taste receptor T1R3, and then treats and relieves neurodegenerative diseases. The application is proved by animal experiments that cognitive dysfunction of AD model mice can be improved in a full range of molecular mechanisms, cell functions, tissue metabolisms and whole behavior, and a variety of dosage forms and medication strategies can be selected, and the application has good in-vivo safety and clinical transformation potential.
Owner:NANJING MEDICAL UNIV

Synthetic nucleic acids containing astrocyte-directed promoter constructs and methods of use thereof

Synthetic nucleic acids are described that can be used for astrocyte-directed expression of heterologous nucleotide sequences, as well as methods of using same for astrocyte-directed expression of such nucleotide sequences for the treatment of neurodegenerative diseases.
Owner:ELI LILLY & CO

Method for constructing astrocytes serving as smoke disease model

The invention discloses a method for constructing astrocytes serving as a smoke disease model, and belongs to the technical field of crossing of stem cells and neuroscience. The method comprises the following steps: S1) reprogramming CD34 + cells in in-vitro PBMCs (peripheral blood mononuclear cells) of smoke disease patients carrying and not carrying RNF213p.R4810K mutation to obtain induced pluripotent stem cells; and S2) directionally inducing and differentiating the induced pluripotent stem cells into astrocytes through a neural progenitor cell way, wherein the obtained astrocytes are the astrocytes capable of being used as the smoke disease model. The astrocyte model prepared by the invention can be used for researching pathogenesis, nerve-blood vessel interaction process and blood-brain barrier (BBB) related functions of smoke diseases, and can be further applied to molecular typing of diseases and in-vitro function evaluation of candidate drugs.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Method for the revival of microglia and astrocytes and applications thereof

Methods are described for treatment of Alzheimer's Disease as well as other neurodegenerative disorders in which microglia and / or astrocyte abilities have been altered and impaired. Methods include brain-targeting of PD-L1 using a brain targeted nanogel loaded with PDL1 antibody and functionalized with two particular targeting ligands. The nanogels can successfully cross the blood brain barrier to release the antibody and reduce PD-L1 expression in the brain while preserving the integrity of the BBB.
Owner:UNIVERSITY OF SOUTH CAROLINA

Assays and methods of use of those assays in the care and diagnosis of stroke patients

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.
Owner:NANOSOMIX +1

Application of Chi3l1 as target spot in preparation of medicine for preventing or treating secondary brain injury after cerebral hemorrhage

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

Injectable piezoelectric hydrogel for spinal cord injury part as well as preparation method and application of injectable piezoelectric hydrogel

The invention belongs to the technical field of medicines, and relates to injectable piezoelectric hydrogel for a spinal cord injury part as well as a preparation method and application of the injectable piezoelectric hydrogel. According to the hydrogel, methacrylated gelatin is used as a carrier, and a piezoelectric material MOF (at) PDA (at) M0, namely MP (at) M, of an enveloping porous structure is loaded in the hydrogel. The hydrogel can achieve dual functions under the ultrasonic action: (1) MP (at) M has piezoelectricity, ultrasonic mechanical energy is converted into electrical stimulation, calcium ion inward flow of astrocytes is triggered, mitochondria is promoted to be transferred from the astrocytes to neurons, and the mitochondrial function of the neurons is recovered; (2) the CD73 enzyme carried by the microglial cell membrane coated on the surface of the MP (at) M can degrade pro-inflammatory ATP (adenosine triphosphate) at the damaged part to generate adenosine, so that astrocytes are promoted to release lactic acid, and rapid energy support is provided for neurons. Mitochondrial transfer and energy supply are synchronously promoted through ultrasonic stimulation, neuronal plasticity is remodeled, spinal cord axon regeneration is promoted, and a new strategy is provided for spinal cord injury treatment.
Owner:CHINA PHARM UNIV

A method for constructing a three-dimensional in vitro blood-brain barrier model with barrier function and its application

This invention discloses a method for constructing a three-dimensional in vitro blood-brain barrier model with barrier function and its application, belonging to the biomedical field. The method includes: preparing a light-controlled biofunctionalized hydrogel with methacrylamide gelatin as the main framework; preparing a suspension of neurovascular matrix components using astrocytes and neurons; uniformly mixing the light-controlled biofunctionalized hydrogel and the neurovascular matrix component suspension to obtain a homogeneous cell-hydrogel composite solution, and preparing it into three-dimensional hydrogel microspheres; transferring the three-dimensional hydrogel microspheres to the bottom of a Transwell culture dish insert to form a stable neurolateral matrix layer; and adding a suspension of brain microvascular endothelial cells into the lower chamber of the Transwell culture dish. This invention achieves the synergistic effect of multiple bioactive substances, overcoming the shortcomings of the single bioactive substance loading method in the prior art.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Polypeptide simulating Ascl1 and application thereof

The invention provides a polypeptide simulating Ascl1 and application thereof, and relates to the technical field of biomedicine, and the technical key point is that the polypeptide simulating Ascl1 is provided, the polypeptide is a TAT-Ascl1-EL-1 polypeptide, and the sequence of the TAT-Ascl1-EL-1 polypeptide is as shown in SEQ ID: NO 01. According to the application, through a verification experiment, the TAT-Ascl1-EL-1 polypeptide is successfully screened out, and in vitro, the polypeptide can be used for effectively reprogramming rat spinal cord reactive astrocytes into neuron-like cells; and a new selectable way is provided for the medical research on cell replacement treatment and cell regeneration after SCI.
Owner:NANTONG UNIV

Synthetic nucleic acids including astrocyte directed promoter constructs and methods of use thereof

Synthetic nucleic acids that can be used for astrocyte directed expression of heterologous nucleotide sequences are described. Also described are methods of using the same for the targeted expression of astrocytes of such nucleotide sequences for the treatment of neurodegenerative diseases.
Owner:ELI LILLY & CO

Research method of influence of S100A9 on AQP4 and influence mechanism thereof

The invention discloses a method for researching the influence of S100A9 on AQP4 and an influence mechanism of the S100A9, and relates to the technical field of biomedicine. Comprising the following steps: cell culture; the method comprises the following steps: inoculating U251 astroglioma cells or SD (Sprague Dawley) rat primary astroglioma cells into a culture dish, after the cells are completely adhered to the wall, replacing a culture medium containing S100A9 proteins with different concentrations, and continuously culturing for 12 hours; the cell activity is detected through CCK8; and adding a CCK8 reagent into the culture dish, incubating for a period of time, and detecting the activity of each group of cells. The invention provides a systematized and detailed research method, and the influence of the S100A9 on the AQP4 can be clarified; through the experimental steps of cell culture, CCK8 detection, Western Blot, RT-qPCR and the like, the change of the S100A9 on the expression and positioning of the AQP4 under different concentrations can be comprehensively known.
Owner:CHONGQING MEDICAL UNIVERSITY

Compositions and methods of treating, preventing, or delaying the progression of neurodegenerative disease

PCT designated stage expiredWO2025042663A1Nervous disorderVectorsMedicineProtein aggregation
Methods for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARa expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Application of inhibitor for targeted inhibition of COLLAGEN pathway in preparation of medicine for treating Alzheimer disease related to exposure of micro-nano plastic particles

The invention discloses an application of an inhibitor for targeted inhibition of a COLLAGEN pathway in a drug for treating Alzheimer's disease (AD) related to exposure of micro-nano plastic particles (MNPs). The research shows that the exposure of the MNPs can activate a COLLAGEN signal channel among astrocytes, microglia and neurons, promote COL1A1 / COL1A2-ITGA1 / ITGB1 mediated abnormal cell communication, cause the M1 type polarization of the microglia, the activation of the p38-MAPK channel of the neurons and the deposition of A beta, and further accelerate the progress of AD (Alzheimer's disease). The pathway is blocked by knocking down the ligand COL1A1 in astrocytes, so that neuroinflammation can be remarkably reduced, A beta accumulation can be inhibited, and the cognitive function can be improved. The invention provides a new molecular target for the treatment of the MNPs related AD.
Owner:SOUTHERN MEDICAL UNIVERSITY